European Journal of Internal Medicine
Volume 19, Issue 8 , Pages 579-586 , December 2008

New treatment options for immune-mediated hematological disorders

  • Daan Dierickx

      Affiliations

    • UZ Gasthuisberg, Department of Hematology, Leuven, Belgium
    • Corresponding Author InformationCorresponding author.
    • ,
  • Anja De Rycke

      Affiliations

    • UZ Gasthuisberg, Department of Internal Medicine, Leuven, Belgium
    • ,
  • Steven Vanderschueren

      Affiliations

    • UZ Gasthuisberg, Department of Internal Medicine, Leuven, Belgium
    • ,
  • André Delannoy

      Affiliations

    • Hôpital de Jolimont, Department of Hematology, Haine-Saint-Paul, Belgium

Received 14 June 2007 ,Accepted 28 August 2007.

References 

  1. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol. 2002;69(4):258–271
  2. Trivedi DH, Bussel JB. Immunohematologic disorders. J Allergy Clin Immunol. 2003;111(2Suppl):S669–S676[21]
  3. Semple JW, Freedman J. Autoimmune pathogenesis and autoimmune hemolytic anemia. Semin Hematol. 2005;42(3):122–130
  4. Dacie SJ. The immune haemolytic anaemias: a century of exciting progress in understanding. Br J Haematol. 2001;114(4):770–785
  5. Norton A, Roberts I. Management of Evans syndrome. Br J Haematol. 2006;132(2):125–137
  6. King KE, Ness PM. Treatment of autoimmune hemolytic anemia. Semin Hematol. 2005;42(3):131–136
  7. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol. 2002;29(1 Suppl 2):2–9
  8. Quartier P, Brethon B, Philippet P, Landman-Parker J, Le Deist F, Fischer A. Treatment of childhood autoimmune haemolytic anaemia with rituximab. Lancet. 2001;358:1511–1513
  9. Gupta N, Kavuru S, Patel D, Janson D, Driscoll N, Ahmed S, et al. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia. Leukemia. 2002;16(10):2092–2095
  10. Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, et al. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. Blood. 2003;101:3857–3861
  11. Trapé G, Fianchi L, Lai M, Laurenti L, Piscitelli R, Leone G, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. Haematologica. 2003;88(2):223–225
  12. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo Clin Proc. 2003;78(11):1340–1346
  13. Camou F, Viallard JF, Pellegrin JL. Rituximab in cold agglutinin disease. Rev Med Interne. 2003;24(8):501–504
  14. Berentsen S, Ulvestad E, Gjertsen BT, Hjort-Hansen H, Langholm R, Knutsen H, et al. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients. Blood. 2004;103(8):2925–2928
  15. Schöllkopf C, Kjeldsen L, Bjerrum OW, Mourits-Andersen HT, Nielsen JL, Christensen BE, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47(2):253–260
  16. D'Arena G, Laurenti L, Capalbo S, D'Arco AM, De Filippi R, Marcacci G, et al. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia. Am J Hematol. 2006;81(8):598–602
  17. D'Arena G, Califano C, Anninziata M, Tartarone A, Capalbo S, Villani O, et al. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients. Eur J Haematol. 2007;March 28; [Electronic publication ahead of print]
  18. Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, et al. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001;114(4):891–898
  19. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995–1008
  20. Provan D, Newland A, Norfolk D, Bolton-Maggs P, Lilleyman J, Greer I, et al. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children, and in pregnancy. Br J Haematol. 2003;120:574–596
  21. Cooper N, Bussel J. The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol. 2006;133(4):364–374
  22. Beardsley DS. ITP in the 21st century. Hematology Am Soc Hematol Educ Program. 2006;402–407
  23. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood. 2005;106(7):2244–2251
  24. Chong BH, Ho SJ. Autoimmune thrombocytopenia. J Thromb Haemost. 2005;3(8):1763–1772
  25. Bussel J. Treatment of immune thrombocytopenic purpura in adults. Semin Hematol. 2006;43(Suppl 5):S3–S10
  26. Perrotta A, Sunnenberg T, Scott J, et al. Rituxan in the treatment of chronic idiopathic thrombocytopenia purpura (ITP). Blood. 1999;94:14a
  27. Saleh MN, Gutheil J, Moore M, Bunch PW, Butler J, Kunkel L, et al. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia. Semin Oncol. 2000;27(Suppl 12):99–103
  28. Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001;98:952–957
  29. Giagounidis AA, Anhuf J, Schneider P, Germing U, Söhngen D, Quabeck K, et al. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study. Eur J Haematol. 2002;69:95–100
  30. Zaja F, Vianelli N, Sperotto A, De Vita S, Iacona I, Zaccaria A, et al. B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica. 2003;88(5):538–546
  31. Narang M, Penner JA, Williams D. Refractory autoimmune thrombocytopenic purpura: responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab). Am J Hematol. 2003;74(4):263–267
  32. Cooper N, Stasi R, Cunningham-Rundles S, Feuerstein MA, Leonard JP, Amadori S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232–239
  33. Sanal SM, Hanson MJ, Dees MS, Sylvester LS, Sullivan JW, Marsland TA, et al. Rituximab induces high response rates and prolonged remission in chronic idiopathic thrombocytopenic purpura (ITP). Blood. 2004;104:3956a
  34. Zalzaleh G, Jajeh A, Tamoseviciene D. Rituximab in the treatment of adults with chronic idiopathic thrombocytopenic purpura (ITP) and autoimmune hemolytic anemia. Blood. 2004;104:3930a
  35. Jacoub J, Mchlayeh W, Tabbara E, Dave HP, Siegel R, Schechter GP. The use of anti-CD20 chimeric monoclonal antibody, rituximab in adult patients with treatment refractory immune thrombocytopenia. Blood. 2004;104:3950a
  36. Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol. 2005;78(4):275–280
  37. Case DC, Hedlund JA, Ebrahim KS, Boyd MA. Rituximab produces long-term responses in immune thrombocytopenic purpura (ITP). Blood. 2005;106:3977a
  38. Garcia-Chavez J, Vela-Ojeda J, Gonzales-Acosta JC, Ovilla-Martinez R. Treatment of refractory chronic immune thrombocytopaenic purpura (ITP) with rituximab: report of a case series. Blood. 2005;106:4007a
  39. Ahn ER, Bidot CJ, Fontana V, Dudkiewicz P, Wenche JY, Horstman L, et al. Rituximab therapy induces long lasting clinical remissions and reduction of anti-platelet glycoprotein autoantibodies in patients with chronic immune thrombocytopenic purpura (ITP). Blood. 2005;106:4006a
  40. Narat S, Gandla J, Hoffbrand AV, Hughes RG, Mehta AB, et al. Rituximab in the treatment of refractory autoimmune cytopenias in adults. Haematologica. 2005;90(9):1273–1274
  41. Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107:2639–2642
  42. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Siqouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25–33
  43. Kuwana M, Normura S, Fujimura K, Nagasawa T, Muto Y, Kurata Y, et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood. 2004;103:1229–1236
  44. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457–3469
  45. Kuter DJ. New thrombopoietic growth factors. Blood. Feb 8 2007;[Electronic publication ahead of print]
  46. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241–3248
  47. Bussel JB, Kuter DJ, George JN, McMillan R, Aledort LM, Conklin GT, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355:1672–1681
  48. Kuter DJ, Bussel JB, George J, Aledort L, Lichtin A, Lyons R, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood. 2006;108:476a
  49. Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, et al. Phase I clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist. Blood. Feb 27 2007;[Electronic publication ahead of print]
  50. Bussel JB, Cheng G, Saleh M, Kovaleva L, Stone N, Mayer B, et al. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): a randomized, double-blind, placebo-controlled trial of eltrombopag, an oral platelet growth factor. Blood. 2006;108:475a
  51. Murrin RJ, Murray JA. Thrombotic thrombocytopenic purpura: aetiology, pathophysiology and treatment. Blood Rev. 2006;20:51–60
  52. George JN. Thrombotic thrombocytopenic purpura. N Engl J Med. 2006;354(18):1927–1935
  53. Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006;70:423–431
  54. Sadler JE. Thrombotic thrombocytopenic purpura: a moving target. Hematology Am Soc Hematol Educ Program. 2006;415–420
  55. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, et al. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med. 1982;307:1432–1435
  56. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, et al. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and hemolytic–uremic syndrome. N Engl J Med. 1998;339:1578–1584
  57. Tsai HM, Lian EC. Antibodies of von Willebrand factor cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594
  58. Zheng X, Chung C, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–41063
  59. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325:393–397
  60. Chemnitz J, Draube A, Scheid C, Staib P, Schulz A, Diehl V, et al. Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab. Am J Hematol. 2002;71:105–108
  61. Gutterman LA, Kloster B, Tsai HM. Rituximab therapy for refractory thrombotic thrombocytopenic purpura. Blood Cells Mol Diseases. 2002;28(3):385–391
  62. Zheng X, Pallera AM, Goodnough LT, Sadler JE, Blinder MA. Remission of chronic thrombotic thrombocytopenic purpura after treatment with cyclophosphamide and rituximab. Ann Intern Med. 2003;138:105–108
  63. Tsai HM, Shulman K. Rituximab induces remission of cerebral ischemia caused by thrombotic thrombocytopenic purpura. Eur J Haematol. 2003;70:183–185
  64. Ahmad A, Aggarwal A, Sharma D, Dave HP, Kinsella V, Rick ME, et al. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP). Am J Hematol. 2004;77:171–176
  65. Yomtovian R, Niklinski W, Silver B, Sarode R, Tsai HM. Rituximab for chronic recurring thrombotic thrombocytopenic purpura: a case report and review of the literature. Br J Haematol. 2004;124:787–795
  66. Stein GY, Zeidman A, Fradin Z, Varon M, Cohen A, Mittelman M. Treatment of resistant thrombotic thrombocytopenic purpura with rituximab and cyclophosphamide. Int J Hematol. 2004;80(1):94–96
  67. Sallah S, Husain A, Wan JY, Nguyen NP. Rituximab in patients with refractory thrombotic thrombocytopenic purpura. J Thromb Haemost. 2004;2:834–836
  68. Fakhouri F, Teixeira L, Delarue R, Grünfeld JP, Veyradier A. Responsiveness of thrombotic thrombocytopenic purpura to rituximab and cyclophosphamide. Ann Intern Med. 2004;140:314–315
  69. Reddy PS, Deauna-Limayo D, Cook JD, Ganguly SS, Blecke C, Bodensteiner DC, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol. 2005;84:232–235
  70. Koulova L, Alexandrescu D, Dutcher JP, O'Boyle KP, Eapen S, Wiernik PH. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol. 2005;78:49–54
  71. Galbusera M, Bresin E, Noris M, Gastoldi S, Belotti D, Capoferri C, et al. Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood. 2005;106:925–928
  72. Patino W, Sarode R. Successful repeat therapy with rituximab for relapsed thrombotic thrombocytopenic purpura. J Clin Apheresis. 2007;22:17–20
  73. Au WY, Ma ES, Lee TL, Ha SY, Fung AT, Lie AK, et al. Successful treatment of thrombotic microangiopathy after haematopoietic stem cell transplantation with rituximab. Br J Haematol. Apr 3 2007;[Electronic publication ahead of print]
  74. George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apheresis. 2006;21:49–56
  75. Dierickx D, Triffet A, Mineur P, Kentos A, Ferster A, Boulet D, et al. Rituximab therapy for immune anemia and thrombocytopenia: a Belgian registry run by the red cell subcommittee of the Belgian Society for Hematology. Haematologica. 2007;92(Suppl 1):0376a

PII: S0953-6205(08)00079-4

doi: 10.1016/j.ejim.2007.08.012

European Journal of Internal Medicine
Volume 19, Issue 8 , Pages 579-586 , December 2008

Article Tools

* Image Usage & Resolution